3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Specimen Handling
40
Biopsy
32
Magnetic Resonance Spectroscopy
26
pembrolizumab
20
Nivolumab
10
trastuzumab deruxtecan
9
Paclitaxel
9
Carboplatin
9
Radiosurgery
7
Irinotecan
7
Gemcitabine
7
X-Rays
6
Pemetrexed
6
Leucovorin
6
Ipilimumab
6
Fulvestrant
6
Fluorouracil
6
Cetuximab
6
Bevacizumab
6
palbociclib
5
Taxes
5
Oxaliplatin
5
Cisplatin
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
durvalumab
4
Letrozole
4
CTLA-4 Antigen
4
ribociclib
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled